Literature DB >> 3007561

Alpha-human atrial natriuretic polypeptide inhibits steroidogenesis in cultured human adrenal cells.

K Higuchi, H Nawata, K Kato, H Ibayashi, H Matsuo.   

Abstract

The ability of synthetic alpha-human atrial natriuretic polypeptide-(1-28) (alpha hANP) to alter steroidogenesis by human adrenal glands was investigated in primary human adrenal cell cultures. alphahANP (10(-9)-10(-7) M) inhibited basal and ACTH (10(-8) M)-stimulated aldosterone, cortisol, and dehydroepiandrosterone (DHEA) secretion in a dose-dependent manner. alpha hANP inhibited aldosterone (IC50, 1.3 X 10(-8) M) and cortisol (IC50, 0.7 X 10(-8) M) secretion more potently than it did DHEA (IC50, 7.5 X 10(-8) M) secretion. ACTH dose-dependent (10(-10)-10(-8) M) increases in aldosterone, cortisol, and DHEA secretion were significantly inhibited by alpha hANP (10(-8) M). In addition, alpha hANP enhanced the accumulation of intracellular cGMP in a dose-dependent manner. As aldosterone, cortisol, and DHEA secretion from cultured human adrenal cells was inhibited by alpha hANP, the site of inhibition of steroidogenesis by alpha hANP is probably localized in the early pathway of steroidogenesis in human adrenal cells. The results also suggest a link between inhibitory effects of alpha hANP and accumulation of intracellular cGMP.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3007561     DOI: 10.1210/jcem-62-5-941

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  8 in total

1.  Renal and anti-aldosterone actions of vasopressin-2 receptor antagonism and B-type natriuretic peptide in experimental heart failure.

Authors:  Lisa C Costello-Boerrigter; Guido Boerrigter; Alessandro Cataliotti; Gail J Harty; John C Burnett
Journal:  Circ Heart Fail       Date:  2010-02-22       Impact factor: 8.790

2.  Differential effects of transforming growth factor type beta on the growth and function of adrenocortical cells in vitro.

Authors:  M Hotta; A Baird
Journal:  Proc Natl Acad Sci U S A       Date:  1986-10       Impact factor: 11.205

3.  Natriuretic peptides receptors in human aldosterone-secreting adenomas.

Authors:  R Sarzani; G Opocher; M V Paci; A S Belloni; F Mantero; P Dessì-Fulgheri; A Rappelli
Journal:  J Endocrinol Invest       Date:  1999 Jul-Aug       Impact factor: 4.256

4.  Potentiation of atrial natriuretic peptide-stimulated cyclic guanosine monophosphate formation by glucocorticoids in cultured rat renal cells.

Authors:  K Kanda; K Ogawa; N Miyamoto; T Hatano; H Seo; N Matsui
Journal:  Br J Pharmacol       Date:  1989-04       Impact factor: 8.739

5.  Lack of aldosterone inhibition by atrial natriuretic factor in primary aldosteronism: in vitro studies.

Authors:  S Rocco; G Opocher; D D'Agostino; L Leone; F Mantero
Journal:  J Endocrinol Invest       Date:  1989-01       Impact factor: 4.256

6.  Effect of human atrial natriuretic peptide on blood glucose concentrations and hormone stimulation during insulin-induced hypoglycaemia in healthy man.

Authors:  E Jungmann; C Konzok; E Höll; W Fassbinder; K Schöffling
Journal:  Eur J Clin Pharmacol       Date:  1989       Impact factor: 2.953

Review 7.  Atrial natriuretic peptide. An overview of clinical pharmacology and pharmacokinetics.

Authors:  A C Tan; F G Russel; T Thien; T J Benraad
Journal:  Clin Pharmacokinet       Date:  1993-01       Impact factor: 6.447

8.  The effect of acute ACE inhibition on atrial natriuretic peptide.

Authors:  C J Doorenbos; P van Brummelen
Journal:  Br J Clin Pharmacol       Date:  1989       Impact factor: 4.335

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.